* Gene/Networks, of Alameda, Calif., was acquired by Warner-Lambert Co., of Morris Plains, N.J. Terms of Warner-Lambert's acquisition of the genomics company were not disclosed. Gene/Networks' technology will be used in a broad range of applications, Warner-Lambert said.
* Immunomedics Inc., of Morris Plains, N.J., said two recipients of the company's radioactively labeled antibodies will soon reach their third anniversaries in complete remission. One is a 73-year-old New Jersey woman with ovarian cancer, and the other is a 60-year-old man in the Midwest with intermediate-grade non-Hodgkin's lymphoma. Both were deemed terminal when referred for experimental therapy.
* Intercardia Inc., of Research Triangle Park, N.C., and Transcell Technologies Inc., of Monmouth Junction, N.J. said their merger is expected to close May 8. Stockholders have approved the deal. Both companies are majority-owned subsidiaries of Lexington, Mass.-based Interneuron Pharmaceuticals Inc. (See BioWorld Today, Nov. 7, 1997, p. 1.)
* Nexell Therapeutics Inc., of Wilmington, Del., initiated a 30-patient Phase I/II clinical study to evaluate the potential value of using the Isolex 300i Stem Cell Selection System to treat Chronic Granulamatous Disease, a hereditary disease involving a genetic defect in the ability of certain white blood cells to kill bacteria. In the study, Isolex is used to select out from peripheral blood the CD34 (stem) cells, into which a corrected gene is inserted using a retroviral vector. The study is part of a Cooperative Research and Development Agreement with the National Institutes of Health. Nexell is a subsidiary of Vimrx Pharmaceuticals Inc., also of Wilmington.
* Pharmacopeia Inc., of Princeton, N.J., has identified a lead compound for partner Bristol-Myers Squibb Co., of New York. The collaboration centers on Pharmacopeia's screening of small molecule libraries against inflammatory and immunological disease targets. For achieving this research milestone, Pharmacopeia received a cash payment in an undisclosed amount.
* Protein Design Labs Inc., of Mountain View, Calif., granted a worldwide non-exclusive license under its antibody humanization patents to a subsidiary of Elan Corp., of Dublin. The license is for Antegren, Elan's humanized antibody, which is in Phase II clinical testing for multiple sclerosis. Under the terms of the agreement, Elan is paying a non-refundable licensing and signing fee of $1.3 million, and has agreed to a milestone payment and royalties.
* Shaman Pharmaceuticals Inc., of South San Francisco, received notification from the FDA that its anti-diarrhea compound, SP-303/Provir, has received fast-track designation for diarrhea in patients with AIDS. The drug is being evaluated in Phase III trials that began in March. Provir is derived from an extract of the croton plant, found in Latin America. Rather than attacking infectious microbes or inhibiting gastrointestinal activity, the drug targets the underlying cellular mechanism for diarrhea by blocking chloride secretion. (See BioWorld Today, Oct. 31, 1997, p. 1.)
* Techniclone Corp., of Tustin, Calif., reported results of a study of vascular endothelial growth factor (VEGF) as a marker of tumor endothelium, indicating several antibodies developed by researchers at the University of Texas Southwestern Medical Center had a high affinity for binding to the VEGF receptor complex.
* SafeScience Inc., of Boston, said its common stock has moved from the Over the Counter (OTC) Bulletin Board and is now trading on the NASDAQ Small Cap Market under the symbol SAFS. SafeScience, which has an anti-cancer carbohydrate product in clinical trials, changed its name earlier this year from IGG International Inc.
* Somatogen Inc., of Boulder, Colo., said its board of directors has approved the redemption of all of Somatogen's outstanding preferred share purchase rights for $0.01 per right, contingent on the approval of stockholders of the planned merger with Baxter International Inc., of Deerfield, Ill., and its subsidiary, RHB1 Acquisition Corp. (See BioWorld Today, Feb. 25, 1998, p. 1.)